Clinical trial · Interventional
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis
Combination Treatment of TACE With Recombinant Human Endostatin Administrated Via Hepatic Artery in Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate safety and potential therapeutic benefits for patients with hepatocellular carcinoma by transcatheter chemoembolization with the recombinant endostatin (commercially available in China)which is also administrated via the hepatic artery. The hypothesis of this protocol is that TACE with antiangiogenic treatment may inhibit the proangiogenic effects induced by the hypoxia of TACE.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transcatheter Arterial Chemoembolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- All patients of this arm are treated by TACE together with Andostatin.
- interventionNames
- Procedure: Transcatheter Arterial Chemoembolization
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
- interventionNames
- Procedure: Transcatheter Arterial Chemoembolization
Primary outcomes (1)
- measure
- Safety and tolerability, Mortality
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with cytologically or histologically documented HCC, who are candidates for TACE * Child-Pugh Child A or B * Age \>= 18 * Measurable disease by RECIST criteria; * Performance status ECOG 0-2 * Previous local therapy completed \> 4 weeks * Written informed consent signed * Normal organ and marrow function defined as: Haematopoietic: * WBC ≥ 3,000/µlplatelet count \> 80,000/mm3 * haemoglobin \> 9g/dL * Hepatic: Albumin ≥ 2.8 g/dl.serum total bilirubin ≤ 3 mg/dl; AST or ALT \< 5 x ULN * Renal: creatinine \< 1.5 x ULN Exclusion Criteria: * Metastases * Prior or concomitant chemotherapy or radiation therapy * VEGF/VEGFR- inhibitors or other anti-angiogenesis agents * Severe and/or uncontrolled medical conditions: * Congestive heart failure, serious cardiac arrhythmia, active coronary artery * Severe renal impairment * Patients who anticipate receiving major surgery during the course of the * Pregnant or breastfeeding patients * Evidence of bleeding diathesis
References
Publications (0)
Data not yet available